Knight Therapeutics Inc. (GUD.TO)
CAD 5.72
(-0.17%)
CAD 5.72
(-0.17%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.89 Million CAD | 367.42% |
| 2022 | -2.4 Million CAD | 54.85% |
| 2021 | -5.32 Million CAD | -54.84% |
| 2020 | -3.43 Million CAD | -124.57% |
| 2019 | 13.98 Million CAD | 341.85% |
| 2018 | -5.78 Million CAD | 35.07% |
| 2017 | -8.9 Million CAD | -13.65% |
| 2016 | -7.83 Million CAD | 30.7% |
| 2015 | -11.3 Million CAD | -124.73% |
| 2014 | -5.03 Million CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 4.49 Million CAD | 68.95% |
| 2024 Q1 | 2.66 Million CAD | 9951.85% |
| 2023 Q2 | -110 Thousand CAD | -101.24% |
| 2023 FY | 6.42 Million CAD | 367.42% |
| 2023 Q4 | -27 Thousand CAD | -102.9% |
| 2023 Q3 | 930 Thousand CAD | 945.45% |
| 2023 Q1 | 8.89 Million CAD | 229.85% |
| 2022 Q2 | 4.98 Million CAD | 363.87% |
| 2022 FY | -2.4 Million CAD | 54.85% |
| 2022 Q4 | -6.84 Million CAD | -324.75% |
| 2022 Q3 | -1.61 Million CAD | -132.36% |
| 2022 Q1 | 1.07 Million CAD | 107.34% |
| 2021 Q2 | 16 Thousand CAD | 100.72% |
| 2021 Q1 | -2.23 Million CAD | 81.91% |
| 2021 Q4 | -14.63 Million CAD | -463.94% |
| 2021 FY | -5.32 Million CAD | -54.84% |
| 2021 Q3 | 4.02 Million CAD | 25031.25% |
| 2020 Q2 | -3.1 Million CAD | 58.34% |
| 2020 FY | -3.43 Million CAD | -124.57% |
| 2020 Q3 | -7.73 Million CAD | -148.87% |
| 2020 Q4 | -12.35 Million CAD | -59.7% |
| 2020 Q1 | -7.46 Million CAD | -333.47% |
| 2019 Q2 | -3.69 Million CAD | -11.07% |
| 2019 Q1 | -3.32 Million CAD | -191.75% |
| 2019 Q4 | -1.72 Million CAD | 56.12% |
| 2019 FY | 13.98 Million CAD | 341.85% |
| 2019 Q3 | -3.92 Million CAD | -6.26% |
| 2018 FY | -5.78 Million CAD | 35.07% |
| 2018 Q4 | -1.13 Million CAD | 2.57% |
| 2018 Q2 | -1.96 Million CAD | -30.13% |
| 2018 Q1 | -1.51 Million CAD | 8.71% |
| 2018 Q3 | -1.16 Million CAD | 40.51% |
| 2017 Q3 | -2.58 Million CAD | -0.98% |
| 2017 Q2 | -2.55 Million CAD | -21.17% |
| 2017 Q1 | -2.11 Million CAD | 14.74% |
| 2017 FY | -8.9 Million CAD | -13.65% |
| 2017 Q4 | -1.65 Million CAD | 35.97% |
| 2016 FY | -7.83 Million CAD | 30.7% |
| 2016 Q1 | -1.7 Million CAD | 7.45% |
| 2016 Q4 | -2.47 Million CAD | -77.87% |
| 2016 Q2 | -2.26 Million CAD | -33.0% |
| 2016 Q3 | -1.39 Million CAD | 38.54% |
| 2015 Q3 | -3.87 Million CAD | -42.75% |
| 2015 Q4 | -1.84 Million CAD | 52.52% |
| 2015 FY | -11.3 Million CAD | -124.73% |
| 2015 Q1 | -2.87 Million CAD | -19.13% |
| 2015 Q2 | -2.71 Million CAD | 5.7% |
| 2014 Q4 | -2.41 Million CAD | -24.99% |
| 2014 Q3 | -1.93 Million CAD | -230.95% |
| 2014 Q2 | -584.2 Thousand CAD | -498.05% |
| 2014 Q1 | -97.68 Thousand CAD | 0.0% |
| 2014 FY | -5.03 Million CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q3 | 375.19 Thousand CAD | 0.0% |
| 2012 Q3 | 61.64 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aurora Cannabis Inc. | -46.45 Million CAD | 93.779% |
| Avicanna Inc. | -7.93 Million CAD | 63.57% |
| Avant Brands Inc. | -1.45 Million CAD | -99.173% |
| Cardiol Therapeutics Inc. | -29.78 Million CAD | 90.297% |
| Crescita Therapeutics Inc. | -1.95 Million CAD | -47.751% |
| MediPharm Labs Corp. | -18.25 Million CAD | 84.166% |
| OrganiGram Holdings Inc. | -242.73 Million CAD | 98.809% |
| Canopy Growth Corporation | -228.71 Million CAD | 98.736% |
| Willow Biosciences Inc. | -13.18 Million CAD | 78.076% |
| Auxly Cannabis Group Inc. | -19 Million CAD | 84.793% |